Robbins LLP Informs Nektar Therapeutics Investors About Class Action Lawsuit for Potential Misrepresentation

Overview of the Nektar Therapeutics Class Action Lawsuit

Robbins LLP, a law firm recognized for defending shareholders' rights, is reaching out to individuals who invested in Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025, and December 15, 2025, to inform them about a class action lawsuit that has been filed. The firm alleges that Nektar may have misrepresented crucial information about its clinical trial outcomes, which potentially impacted the investments of shareholders during this period.

Background of Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that focuses on developing therapies aimed at modulating the immune system to treat various autoimmune disorders. Their primary candidate, rezpegaldesleukin (commonly known as REZPEG or NKTR-358), is aimed at treating conditions such as alopecia areata. The significance of these treatments underlines why the allegations of misrepresentation are particularly troubling for investors.

The Allegations Against Nektar Therapeutics

Central to the allegations is the claim that during the designated class period, Nektar failed to reveal critical information regarding the REZOLVE-AA trial. The lawsuit outlines that the enrollment within this trial did not follow the applicable regulatory protocols. Hence, the trial outcomes may not reflect the true efficacy of the candidate medications.

Systematic failures allegedly affected the integrity, and the announced results for the REZOLVE-AA trial were believed to have been overstated, causing misleading public statements by the company's executives. Following the company’s announcement on December 16, 2025, that the trial did not achieve statistical significance—with reasons given that non-eligible patients were included—the stock price dropped sharply, indicating the market's reaction to the altered expectations.

Impact on Investors

On December 16, 2025, following the news release about the trial results, Nektar’s stock plummeted by 7.77%, reducing the share price from $53.30 to $49.16. This significant drop has raised concerns among shareholders, many of whom may feel deceived by the optimism previously presented by Nektar regarding the drug’s prospects.

Your Rights as an Investor

Investors who feel they have been misled by Nektar's alleged misstatements are encouraged to join the class action. Robbins LLP is actively seeking individuals who may be interested in serving as lead plaintiffs. A lead plaintiff represents the interests of all participants in the class action. For those who choose to remain uninvolved, they can still maintain their status as absent class members, without the obligation to actively engage in legal proceedings.

No Fees Unless Successful

Importantly, Robbins LLP operates on a contingency fee basis, meaning that shareholders are not required to pay any legal fees or expenses unless the case is successful. This approach allows investors to seek justice and potential recovery without upfront financial risk.

About Robbins LLP

Founded in 2002, Robbins LLP has established itself as a leader in shareholder rights litigation. The firm has a consistent track record of helping shareholders recover from financial losses, improve corporate governance, and hold executives accountable for their actions. Investor support is vital in these legal endeavors, and Robbins LLP encourages all affected shareholders to consider participating in the class action.

Next Steps

If you have purchased Nektar Therapeutics securities during the specified period, you may receive important updates regarding the progress of this class action and any potential recovery. For further information about your rights and to see how you can get involved, reach out to Robbins LLP through their web portal or contact them directly via email or phone.

For continuous updates regarding similar lawsuits and shareholder rights, subscribing to the firm's alerts can keep investors informed and empower them to act on behalf of their interests.